Hudson Bay Capital Management
RLMD icon

Hudson Bay Capital Management’s Relmada Therapeutics RLMD Stock Holding History

Hudson Bay Capital Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$293K Buy
42,141
+15,894
+61% +$75.2K ﹤0.01% 1036
2025
Q4 		$127K Buy
+26,247
New +$87.9K ﹤0.01% 1001

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Hudson Bay Capital Management's RLMD Position: Q1 2026 in Review

Hudson Bay Capital Management increased its Relmada Therapeutics (RLMD) stake by 61% in Q1 2026, buying an estimated $75.2K and bringing the position to 42,141 shares worth $293K. The position accounts for ﹤0.01% of the portfolio, ranked #1036.

Hudson Bay Capital Management first reported a position in RLMD in Q4 2025 and has held it in 2 quarters since. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Hudson Bay Capital Management held 42,141 shares of Relmada Therapeutics worth $293K as of Q1 2026.
  • Hudson Bay Capital Management bought 15,894 Relmada Therapeutics shares in Q1 2026, an estimated $75.2K.
  • Relmada Therapeutics made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q1 2026, its #1036 holding.
  • Hudson Bay Capital Management first reported a position in Relmada Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.